The Pharmacy Benefit Manager Sunshine and Accountability Act requires Pharmacy Benefit Managers (PBMs) to publicly disclose detailed financial information about their contracts with drug manufacturers and health plans. Specifically, PBMs must report total rebates received, administrative fees collected, amounts retained (not passed through to health plans), and the retained rebate percentage for each contract. This data, including the highest and lowest retained rebate percentages across all contracts, must be submitted annually to the Department of Health and Human Services and published on a public website. The bill directly affects PBMs and the health plans/insurance issuers they serve by increasing transparency in how drug pricing and rebates are managed.
The Pharmacy Benefits Manager Accountability Act requires pharmacy benefits managers (PBMs) and health insurance issuers to provide detailed annual reports to plan sponsors (like employers) about drug spending, rebates, and formulary decisions. These reports must include specific data on drugs dispensed, costs, patient out-of-pocket spending, rebates received from manufacturers, and net spending after rebates, all in machine-readable format. The bill establishes penalties of up to $10,000 per day for failure to provide required information and $100,000 per item for false information. It also directs a GAO study on pharmacy networks and common ownership structures to assess potential anti-competitive practices.
The Working Families Task Force Act of 2023 establishes a federal task force led by the Secretary of Labor, including representatives from eight departments (including Health, Education, Housing, and Treasury), to examine challenges facing working families. The task force will identify key issues like affordable childcare, housing access, livable wages, and tax credit effectiveness, then develop policy recommendations to improve their standard of living. It must meet quarterly, submit an initial report within 180 days, and provide annual updates to relevant congressional committees. The bill directly affects working families by creating a coordinated federal effort to address their economic challenges through agency collaboration. It does not create new programs but mandates a review of existing policies to inform future legislative action.
This bill establishes minimum nurse-to-patient ratios for registered nurses in hospital units (such as 1:1 in trauma units, 2:1 in critical care units, and 3:1 in emergency rooms), requiring hospitals to develop and maintain staffing plans that meet these standards. It mandates transparency in documenting staffing levels, ensures hospitals verify nurses' competence for specific units, and enforces compliance through Medicare and Medicaid programs with penalties for violations. The bill protects nurses who refuse unsafe assignments due to staffing concerns and includes initiatives to improve nurse retention and address staffing shortages. It directly affects hospitals, nurses, and patients by aiming to improve patient safety and care quality through standardized staffing requirements. The bill applies to all hospitals, with extended implementation timelines for rural facilities.
HR 2474, the "Strengthening Medicare for Patients and Providers Act," changes how Medicare pays physicians for services. It replaces the previous two-part payment system (used through 2025) with a single annual payment rate update starting in 2024. This update will be based on the Medicare Economic Index (MEI), which tracks costs for medical providers. The change directly affects Medicare-certified doctors and clinics who receive payments under the physician fee schedule.
This bill would require Medicare to cover FDA-approved blood tests that screen for multiple cancers simultaneously (like breast, lung, or colorectal cancer) for beneficiaries. It directly affects Medicare recipients aged 65+ who could access these new screenings once per year, without prior authorization. The key provision adds "multi-cancer early detection screening tests" to Medicare's covered services under Part B, defining them as blood tests analyzing cell-free DNA, while maintaining existing coverage for standard screenings like mammograms. The bill does not change current coverage for individual cancer screenings but ensures Medicare keeps pace with new medical technology.
This bill modifies Medicare's rules for clinical laboratory testing to reduce administrative burdens. It requires the use of statistically valid sampling (instead of full reporting) for "widely available" tests - defined as tests costing under $1,000 per test with over 100 labs performing them - to determine payment rates starting in 2026. The bill also delays reporting deadlines until 2027, updates how labs are defined for payment purposes, and adds annual payment increase caps (2.5% for common tests in 2024-2025, rising to 5% by 2028). These changes directly affect Medicare-participating labs, particularly independent and hospital-based labs conducting common tests.
This bill requires Medicare, Medicaid, and CHIP to cover advanced genetic cancer testing (like DNA/RNA sequencing and their interpretation) for patients diagnosed with cancer. It defines covered tests as next-generation sequencing performed by clinical labs and limits coverage to once per diagnosis, recurrence, or treatment monitoring. Medicare will pay 80% of the test cost (or 100% if billed under assignment), while Medicaid and CHIP must include these tests in mandatory coverage starting January 1, 2025. The bill directly affects cancer patients enrolled in these federal health programs by ensuring access to specific genetic testing without excessive out-of-pocket costs.
This bill requires private health insurance plans and Medicaid to cover selected insulin products for individuals under 26 years old without deductibles and with cost-sharing capped at $35 per 30-day supply or 25% of the negotiated price (whichever is lower). It defines "selected insulin products" as at least one of each type (e.g., rapid-acting, long-acting) and form (e.g., vial, pump) of insulin that plans select. The cost-sharing for these products counts toward the plan’s annual out-of-pocket maximum, and the requirement applies to all private plans and Medicaid starting January 1, 2024. Plans are not required to cover insulin from out-of-network providers at the same cost-sharing level.
HR 1610 would modernize Medicare coverage for chiropractic care by removing the current restriction that limited beneficiaries to one chiropractic service per visit. It expands coverage to include all services provided by licensed chiropractors within their state-authorized scope, aligning Medicare with VA, military, and private insurance practices. The bill requires chiropractors to complete a Secretary-approved educational webinar to cover non-spinal services, while still allowing payment for spinal manipulation treatments without this requirement. This directly affects Medicare beneficiaries seeking chiropractic care and chiropractors seeking Medicare reimbursement for their services.
The Affordable Insulin Now Act (HR 1488) requires health insurance plans and issuers to cover specific insulin products with cost-sharing capped at $35 per 30-day supply or 25% of the negotiated price, whichever is lower, starting in 2024. It directly affects people with diabetes who rely on insulin by limiting out-of-pocket costs for covered products. The bill mandates coverage of all insulin types (rapid-acting, long-acting, etc.) and dosage forms (vials, pumps, etc.) as selected by the plan. This applies to both group and individual health insurance plans under the Public Health Service Act, Internal Revenue Code, and ERISA, with cost-sharing counting toward annual deductibles.
HR 1399, the "Protect Children's Innocence Act," prohibits medical gender-affirming care for minors under 18 by making it a class C felony for providers to perform such care. The bill defines gender-affirming care broadly to include surgical procedures, hormone treatments, and certain cosmetic procedures, with exceptions for medical conditions like reproductive cancers or intersex conditions. It prohibits federal funding for gender-affirming care through programs like Medicaid, Medicare, and the Affordable Care Act, and bans such care in federal health facilities. The bill also prevents institutions of higher education from teaching gender-affirming care and adds immigration consequences for individuals who provide such care to minors.
